***News Stories Thread*** ONGOING 2019

Please feel free to read, share your thoughts, your stories and connect with others!
Wewillfight
Posts: 6
Joined: Sun Mar 03, 2019 5:27 am

Hope for advanced MSS stable crc

Postby Wewillfight » Mon Mar 18, 2019 4:48 pm

I guess this may have been posted before but if missed

Hope for advanced MSS stable crc

“Every two weeks, these patients were given 240 mg of nivolumab, while pixatimod was given weekly, starting at a dose of 25 mg, which was determined to be the maximum tolerated dose”

We observed a response in two patients with metastatic CRC: one has had a sustained reduction of 86% in tumour burden for just over twelve months of treatment now, and another remains on treatment for over six months with ongoing reduction of 38% in tumour burden despite a new growth in the bone. One further patient with CRC has stable disease at sixteen weeks. All three patients were confirmed to have microsatellite stable disease. The clinical improvement of the three patients with CRC has allowed them to continue functioning as they did before they developed cancer, including the ability to perform all the activities of daily living. In total, four patients with CRC remain in the study.”

https://www.ecco-org.eu/Global/News/ENA ... ombination

User avatar
CRguy
Posts: 9900
Joined: Sun Feb 10, 2008 6:00 pm

6-Month vs 12-Month Capecitabine as Adjuvant Chemotherapy for Patients With Stage III Colon Cancer

Postby CRguy » Mon Mar 18, 2019 7:26 pm

6-Month vs 12-Month Capecitabine as Adjuvant Chemotherapy for Patients With Stage III Colon Cancer

TAKE-HOME MESSAGE

Patients with stage III colorectal cancer were randomized to receive 6 or 12 months of adjuvant capecitabine. Treatment for 12 months was associated with improved relapse-free and overall survival compared with treatment for 6 months. Disease-free survival at 3 and 5 years was not significantly different between the two groups.

The use of adjuvant capecitabine for 12 months appears to confer relapse-free and overall survival benefits but does not improve disease-free survival.

– Neil Majithia, MD

User avatar
CRguy
Posts: 9900
Joined: Sun Feb 10, 2008 6:00 pm

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Mucinous Histology

Postby CRguy » Mon Mar 18, 2019 7:27 pm

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Mucinous Histology

TAKE-HOME MESSAGE

This retrospective study evaluated the benefit derived from anti-EGFR therapy among patients with RAS/BRAF wild-type metastatic colorectal cancer with and without mucinous histology.

There was no meaningful benefit observed with anti-EGFR therapy among those with either left- or right-sided tumors with mucinous histology.

– Neil Majithia, MD

User avatar
O Stoma Mia
Posts: 1600
Joined: Sat Jun 22, 2013 6:29 am

White Oak woman diagnosed with cancer as a teen shares story in national publication

Postby O Stoma Mia » Wed Mar 20, 2019 12:48 am

White Oak woman diagnosed with cancer as a teen shares story in national publication
https://triblive.com/local/pittsburgh-allegheny/white-oak-woman-diagnosed-with-cancer-as-a-teen-shares-story-in-national-publication/?fbclid=IwAR04W7D839Ic-dSmb2S_dVwK-tGAKz73oF1nRJi6bOkCMg8wJy273o3jD3o
Now the White Oak resident is offering the details of her cancer battle through a feature in “On the Rise,” the national magazine of the nonprofit The Colon Club, with the aim of encouraging others to pay attention to their health.

Beckster
Posts: 367
Joined: Thu Jan 12, 2017 3:01 pm
Location: New Jersey

Does Age at Diagnosis Impact Clinical and Molecular Features of Colorectal Cancer?

Postby Beckster » Thu Mar 21, 2019 6:06 pm

https://www.cancernetwork.com/colorecta ... tal-cancer

Colorectal cancers diagnosed in early adulthood are genetically and clinically distinct, and potentially more aggressive, than colorectal tumors diagnosed at older ages, according to the results of a large analysis of four patient cohorts. The findings were published in the journal Cancer.

Among patients younger than 50 years old, colorectal tumors harbor different genetic mutations and histologic features than those seen in older patients, including synchronous metastases, microsatellite instability, and fewer BRAF V600 mutations, the researchers reported.
57/Female
DX:(CC) 10/19/16
11/4/16- Lap right hemi(cecum)
CEA- Pre Op (1.9), Pre Chemo (2.5)
Type: Adenocarcinoma
Tumor size:3.5 cm x 2.5 x 0.7 cm
Grade: G3 (path) G2 (pre-op)
TNM: T3N0M0/IIA
LN: 0/24
LVI present
Surgical margins: clear
MSS
12/27/2016 - Capeox, anaphylactic reaction to oxaliplatin on first infusion
1/2/17 to 6/9/17- Xeloda monotherapy
6/17, 12/17, 6/18, 12/18, 6/19 CT Scan NED :D
CEA- 6/17- 3.6, 9/17- 2.8 12/17-2.8, 3/18-3.1, 6/18-3.0, 9/18 2.8, 12/18 2.5 3/19 3.1 6/19 3.1
Clear Colonoscopy 10/17 :D

User avatar
O Stoma Mia
Posts: 1600
Joined: Sat Jun 22, 2013 6:29 am

Drinking Coca-Cola and Diet Coke daily 'increases your risk of dying young'

Postby O Stoma Mia » Fri Mar 22, 2019 3:37 am

Drinking Coca-Cola and Diet Coke daily 'increases your risk of dying young'
https://www.birminghammail.co.uk/news/health/drinking-coca-cola-diet-coke-15991736

User avatar
LPL
Posts: 635
Joined: Fri Apr 22, 2016 12:49 am
Location: Europe

Re: Drinking Coca-Cola and Diet Coke daily 'increases your risk of dying young'

Postby LPL » Fri Mar 22, 2019 5:48 am

O Stoma Mia wrote:Drinking Coca-Cola and Diet Coke daily 'increases your risk of dying young'
https://www.birminghammail.co.uk/news/health/drinking-coca-cola-diet-coke-15991736

This article is commenting on the study before it was published
https://www.sciencedaily.com/releases/2 ... 084153.htm
and I believe this is the original study
https://www.ahajournals.org/doi/10.1161 ... 118.037401
DH @ 65 DX 4/11/16 CC recto-sigmoid junction
Adenocarcenoma pt 35x15x9mm G3(biopsi) G1(surgical)
Mets 3 Liver resectable
T4aN1bM1a Stage IVa 2/9 LN
MSS, KRAS-mut G13D
CEA & CA19-9: 5/18 2.5 78 8/17 1.4 48 2/14/17 1.8 29
4 Folfox 6/15-7/30 (b4 liver surgery) 8 after
CT: 8/8 no change 3/27/17 NED->Jan-19 mets to lung
:!: Steroid induced hyperglycemia dx after 3chemo
Surgeries 2016: 3/18 Emergency colostomy
5/23 Primary+gallbl+stoma reversal+port 9/1 Liver mets
RFA 2019: Feb lung met

User avatar
GrouseMan
Posts: 808
Joined: Mon Aug 12, 2013 12:30 pm
Location: SE Michigan USA

Cancer immunotherapy may have a dark side

Postby GrouseMan » Thu Mar 28, 2019 3:49 pm

I see a recent article in Science that will be published soon that there are concerns the possibility that in a few instances that so called checkpoint inhibitors could be the cause of "hyperprogression" seen in a few patients. Some cancer researchers wonder whether it is simply an illusion—whether the patients' tumors were destined to grow rapidly even before checkpoint inhibitor treatment. I have not received this issue yet and may have more details when I do.

Here is a link to the Summary from Science:

http://science.sciencemag.org/content/3 ... id=2739740

Next week in Atlanta at the annual meeting of the AARC, researchers will try to resolve how to pin down whether hyperprogression is real and, if so, how to identify which patients should not receive these increasingly popular drugs.

So we should keep watch on all the things coming out of AACR next week.

Update: More news on this topic. Have a look at the following Link:

https://www.sciencemag.org/news/2019/03 ... id=2741679

GrouseMan
DW 53 dx Jun 2013
CT mets Liver Spleen lung. IVb CEA~110
Jul 2013 Sig Resct
8/13 FolFox,Avastin 12Tx mild sfx, Ongoing 5-FU Avastin every 3 wks.
CEA: good marker
7/7/14 CT Can't see the spleen Mets.
8/16/15 CEA Up, CT new abdominal mets. Iri, 5-FU, Avastin every 2 wks.
1/16 Iri, Erbitux and likely Avastin (Trial) CEA going >.
1/17 CEA up again dropped from Trial, Mets growth 4-6 mm in abdomen
5/2/17 Failed second trial, Hospitalized 15 days 5/11. Home Hospice 5/26, at peace 6/4/2017

User avatar
GrouseMan
Posts: 808
Joined: Mon Aug 12, 2013 12:30 pm
Location: SE Michigan USA

Cancer Preventive Vaccine Showed Promising Results in Preclinical Model of Lynch Syndrome

Postby GrouseMan » Wed Apr 03, 2019 8:17 am

News of interest from AACR:

Cancer Preventive Vaccine Showed Promising Results in Preclinical Model of Lynch Syndrome:

Seems we may one day see a vaccine to help treat people diagnosed with Lynch Syndrome. In a mouse model of Lynch Syndrome they have discovered that treatment with an Oncolytic Vaccine and Naproxen prolonged the life of Mice that model Lynch Syndrome significantly from 241 days for those without treatment to 541 days for those treated with the vaccine and Naproxen!

See: https://www.aacr.org/Newsroom/Pages/New ... temID=1298

Regards,

GrouseMan
DW 53 dx Jun 2013
CT mets Liver Spleen lung. IVb CEA~110
Jul 2013 Sig Resct
8/13 FolFox,Avastin 12Tx mild sfx, Ongoing 5-FU Avastin every 3 wks.
CEA: good marker
7/7/14 CT Can't see the spleen Mets.
8/16/15 CEA Up, CT new abdominal mets. Iri, 5-FU, Avastin every 2 wks.
1/16 Iri, Erbitux and likely Avastin (Trial) CEA going >.
1/17 CEA up again dropped from Trial, Mets growth 4-6 mm in abdomen
5/2/17 Failed second trial, Hospitalized 15 days 5/11. Home Hospice 5/26, at peace 6/4/2017

User avatar
LPL
Posts: 635
Joined: Fri Apr 22, 2016 12:49 am
Location: Europe

Re: Cancer immunotherapy may have a dark side

Postby LPL » Thu Apr 04, 2019 11:51 am

GrouseMan wrote:I see a recent article in Science that will be published soon that there are concerns the possibility that in a few instances that so called checkpoint inhibitors could be the cause of "hyperprogression" seen in a few patients. Some cancer researchers wonder whether it is simply an illusion—whether the patients' tumors were destined to grow rapidly even before checkpoint inhibitor treatment. I have not received this issue yet and may have more details when I do.

Here is a link to the Summary from Science:

http://science.sciencemag.org/content/3 ... id=2739740

Next week in Atlanta at the annual meeting of the AARC, researchers will try to resolve how to pin down whether hyperprogression is real and, if so, how to identify which patients should not receive these increasingly popular drugs.

So we should keep watch on all the things coming out of AACR next week.

Update: More news on this topic. Have a look at the following Link:

https://www.sciencemag.org/news/2019/03 ... id=2741679

GrouseMan

Hi GrouseMan,
My feeling is that this subject should be worthy of its own post!? Are you willing to do that? As a researcher your views and knowledge is something we value highly!

From the paper you linked to https://www.sciencemag.org/news/2019/03 ... id=2741679
Kurzrock noted a clue in her patients with hyperprogression: Most had either mutations in EGFR or extra copies of MDM2 or MDM4, all known cancer genes. Although only some of the other teams studying hyperprogression have confirmed these findings, scientists working with Kurzrock are using cancer cell lines and mouse models that have alterations in these genes to see whether treating them with a checkpoint inhibitor somehow triggers the release of growth-promoting molecules.
DH @ 65 DX 4/11/16 CC recto-sigmoid junction
Adenocarcenoma pt 35x15x9mm G3(biopsi) G1(surgical)
Mets 3 Liver resectable
T4aN1bM1a Stage IVa 2/9 LN
MSS, KRAS-mut G13D
CEA & CA19-9: 5/18 2.5 78 8/17 1.4 48 2/14/17 1.8 29
4 Folfox 6/15-7/30 (b4 liver surgery) 8 after
CT: 8/8 no change 3/27/17 NED->Jan-19 mets to lung
:!: Steroid induced hyperglycemia dx after 3chemo
Surgeries 2016: 3/18 Emergency colostomy
5/23 Primary+gallbl+stoma reversal+port 9/1 Liver mets
RFA 2019: Feb lung met

Beckster
Posts: 367
Joined: Thu Jan 12, 2017 3:01 pm
Location: New Jersey

Video- Does Tumor Biology Play a Role in Colon Cancer Racial Disparities?

Postby Beckster » Sat Apr 06, 2019 2:49 pm

57/Female
DX:(CC) 10/19/16
11/4/16- Lap right hemi(cecum)
CEA- Pre Op (1.9), Pre Chemo (2.5)
Type: Adenocarcinoma
Tumor size:3.5 cm x 2.5 x 0.7 cm
Grade: G3 (path) G2 (pre-op)
TNM: T3N0M0/IIA
LN: 0/24
LVI present
Surgical margins: clear
MSS
12/27/2016 - Capeox, anaphylactic reaction to oxaliplatin on first infusion
1/2/17 to 6/9/17- Xeloda monotherapy
6/17, 12/17, 6/18, 12/18, 6/19 CT Scan NED :D
CEA- 6/17- 3.6, 9/17- 2.8 12/17-2.8, 3/18-3.1, 6/18-3.0, 9/18 2.8, 12/18 2.5 3/19 3.1 6/19 3.1
Clear Colonoscopy 10/17 :D

User avatar
O Stoma Mia
Posts: 1600
Joined: Sat Jun 22, 2013 6:29 am

Widely-Used Food Additive E319 Impairs Immune Responses to Influenza Infection

Postby O Stoma Mia » Tue Apr 09, 2019 10:08 am

Widely-Used Food Additive E319 Impairs Immune Responses to Influenza Infection
http://www.sci-news.com/medicine/e319-immune-responses-influenza-infection-07071.html

mpbser
Posts: 905
Joined: Wed Apr 19, 2017 11:52 am

Another study shows cancer is fueled by sugar

Postby mpbser » Thu Apr 11, 2019 6:03 am

Wife 4/17 Dx age 45
5/17 LAR
Adenocarcinoma
5 x 4 x 1 cm
low grade
T3 N2b M1a
Stage IV A
8/17 Sub-total colectomy
2nd tumor 5.5 cm T1 N0
lymph nodes: 9 of 96
CEA: 2.9 to 2.2
MSS/MSI-L
Lynch no; KRAS wild
Immunohistochemsistry Normal
Tumor: MTOR, APC, TP53
Fall 2017 FOLFOX shrank the 1 met in liver
1/18 Liver left hepatectomy seg 4
5/18 CT clear
12/18 MRI shows 1 liver met
3/7/19 Resection & HAI
4/1/19 Folfiri & FUDR
5/13/19 HAI pump catheter dislodge, nearly hemorrhaged to death
6/10/19 5FU

Beckster
Posts: 367
Joined: Thu Jan 12, 2017 3:01 pm
Location: New Jersey

Success in first phase of human trials for colorectal cancer vaccine

Postby Beckster » Fri Apr 26, 2019 10:49 am

"Success in first phase of human trials for colorectal cancer vaccine".

https://newatlas.com/colon-cancer-vacci ... lts/59432/
57/Female
DX:(CC) 10/19/16
11/4/16- Lap right hemi(cecum)
CEA- Pre Op (1.9), Pre Chemo (2.5)
Type: Adenocarcinoma
Tumor size:3.5 cm x 2.5 x 0.7 cm
Grade: G3 (path) G2 (pre-op)
TNM: T3N0M0/IIA
LN: 0/24
LVI present
Surgical margins: clear
MSS
12/27/2016 - Capeox, anaphylactic reaction to oxaliplatin on first infusion
1/2/17 to 6/9/17- Xeloda monotherapy
6/17, 12/17, 6/18, 12/18, 6/19 CT Scan NED :D
CEA- 6/17- 3.6, 9/17- 2.8 12/17-2.8, 3/18-3.1, 6/18-3.0, 9/18 2.8, 12/18 2.5 3/19 3.1 6/19 3.1
Clear Colonoscopy 10/17 :D

Beckster
Posts: 367
Joined: Thu Jan 12, 2017 3:01 pm
Location: New Jersey

Nonoperative Management May Be Possible for Select Patients With Rectal Cancer

Postby Beckster » Sun Apr 28, 2019 6:19 am

“The main takehome is that there are a clear subset of patients that can be cured of recital cancer without surgery. We just need to better define who those patients are, so that we can comfortably offer this strategy to more patients without putting any of them at risk,” Nurkin told Cancer Network.



https://www.cancernetwork.com/colorecta ... tal-cancer
57/Female
DX:(CC) 10/19/16
11/4/16- Lap right hemi(cecum)
CEA- Pre Op (1.9), Pre Chemo (2.5)
Type: Adenocarcinoma
Tumor size:3.5 cm x 2.5 x 0.7 cm
Grade: G3 (path) G2 (pre-op)
TNM: T3N0M0/IIA
LN: 0/24
LVI present
Surgical margins: clear
MSS
12/27/2016 - Capeox, anaphylactic reaction to oxaliplatin on first infusion
1/2/17 to 6/9/17- Xeloda monotherapy
6/17, 12/17, 6/18, 12/18, 6/19 CT Scan NED :D
CEA- 6/17- 3.6, 9/17- 2.8 12/17-2.8, 3/18-3.1, 6/18-3.0, 9/18 2.8, 12/18 2.5 3/19 3.1 6/19 3.1
Clear Colonoscopy 10/17 :D


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: brokenwings, natelaugh and 41 guests